# Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer

> **NCT00006089** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 34 (actual)

## Conditions studied

- Endometrial Adenocarcinoma
- ERBB2 Gene Amplification
- Recurrent Uterine Corpus Carcinoma
- Stage III Uterine Corpus Cancer AJCC v7
- Stage IV Uterine Corpus Cancer AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Trastuzumab

## Key facts

- **NCT ID:** NCT00006089
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2000-09-18
- **Primary completion:** 2007-09-04
- **Final completion:** 2010-01-31
- **Target enrollment:** 34 (ACTUAL)
- **Last updated:** 2019-07-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00006089

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00006089, "Trastuzumab in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT00006089. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*